The Functional Role of IgA in the IgM/IgA-Enriched Immunoglobulin Preparation Trimodulin

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2021 Dec 24

PMID 34944644

Citations 7

Authors

Fabian Bohlander

Sabrina Weissmuller

Dennis Riehl

Marcus Gutscher

Jorg Schuttrumpf

Stefanie Faust

Affiliations

Soon will be listed here.

Abstract

In comparison to human immunoglobulin (Ig) G, antibodies of IgA class are not well investigated. In line with this, the functional role of the IgA component in IgM/IgA-enriched immunoglobulin preparations is also largely unknown. In recent years, powerful anti-pathogenic and immunomodulatory properties of human serum IgA especially on neutrophil function were unraveled. Therefore, the aim of our work is to investigate functional aspects of the trimodulin IgA component, a new plasma-derived polyvalent immunoglobulin preparation containing ~56% IgG, ~23% IgM and ~21% IgA. The functional role of IgA was investigated by analyzing the interaction of IgA with FcαRI, comparing trimodulin with standard intravenous IgG (IVIG) preparation and investigating Fc receptor (FcR)-dependent functions by excluding IgM-mediated effects. Trimodulin demonstrated potent immunomodulatory, as well as anti-pathogenic effects in our neutrophil model (neutrophil-like HL-60 cells). The IgA component of trimodulin was shown to induce a strong FcαRI-dependent inhibitory immunoreceptor tyrosine-based activation motif (ITAMi) signaling, counteract lipopolysaccharide-induced inflammation and mediate phagocytosis of . The fine-tuned balance between immunomodulatory and anti-pathogenic effects of trimodulin were shown to be dose-dependent. Summarized, our data demonstrate the functional role of IgA in trimodulin, highlighting the importance of this immunoglobulin class in immunoglobulin therapy.

Citing Articles

Immunoglobulin A Antibodies: From Protection to Harmful Roles.

Gleeson P, Camara N, Launay P, Lehuen A, Monteiro R Immunol Rev. 2024; 328(1):171-191.

PMID: 39578936 PMC: 11659943. DOI: 10.1111/imr.13424.

Efficacy and safety of trimodulin in patients with severe COVID-19: results from a randomised, placebo-controlled, double-blind, multicentre, phase II trial (ESsCOVID).

Agafina A, Aguiar V, Rossovskaya M, Fartoukh M, Hajjar L, Thiery G Eur J Med Res. 2024; 29(1):418.

PMID: 39138518 PMC: 11321023. DOI: 10.1186/s40001-024-02008-x.

Effects of Fisch polysaccharide from different regions on growth performance and gastrointestinal microbiota of sheep lambs.

Manafu Z, Zhang Z, Malajiang X, Abula S, Guo Q, Wu Y Front Pharmacol. 2024; 15:1379394.

PMID: 38746008 PMC: 11091474. DOI: 10.3389/fphar.2024.1379394.

Preparation and activity study of Ruoqiang jujube polysaccharide copper chelate.

Moheteer A, Li J, Abulikemu X, Lakho S, Meng Y, Zhang J Front Pharmacol. 2024; 14:1347817.

PMID: 38273828 PMC: 10809154. DOI: 10.3389/fphar.2023.1347817.

Multifaceted Tissue-Protective Functions of Polyvalent Immunoglobulin Preparations in Severe Infections-Interactions with Neutrophils, Complement, and Coagulation Pathways.

Schmidt C, Weissmuller S, Heinz C Biomedicines. 2023; 11(11).

PMID: 38002022 PMC: 10669904. DOI: 10.3390/biomedicines11113022.

References

Hansen I, Hoepel W, Zaat S, Baeten D, Dunnen J . Serum IgA Immune Complexes Promote Proinflammatory Cytokine Production by Human Macrophages, Monocytes, and Kupffer Cells through FcαRI-TLR Cross-Talk. J Immunol. 2017; 199(12):4124-4131. DOI: 10.4049/jimmunol.1700883. View

Brandsma A, Ten Broeke T, Nederend M, Meulenbroek L, van Tetering G, Meyer S . Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing. Cancer Immunol Res. 2015; 3(12):1316-24. DOI: 10.1158/2326-6066.CIR-15-0099-T. View

Pfirsch-Maisonnas S, Aloulou M, Xu T, Claver J, Kanamaru Y, Tiwari M . Inhibitory ITAM signaling traps activating receptors with the phosphatase SHP-1 to form polarized "inhibisome" clusters. Sci Signal. 2011; 4(169):ra24. DOI: 10.1126/scisignal.2001309. View

Didangelos A . COVID-19 Hyperinflammation: What about Neutrophils?. mSphere. 2020; 5(3). PMC: 7316488. DOI: 10.1128/mSphere.00367-20. View

Kakoullis L, Pantzaris N, Platanaki C, Lagadinou M, Papachristodoulou E, Velissaris D . The use of IgM-enriched immunoglobulin in adult patients with sepsis. J Crit Care. 2018; 47:30-35. DOI: 10.1016/j.jcrc.2018.06.005. View

Nimmerjahn F, Ravetch J . Fc-receptors as regulators of immunity. Adv Immunol. 2007; 96:179-204. DOI: 10.1016/S0065-2776(07)96005-8. View

Olas K, Butterweck H, Teschner W, Schwarz H, Reipert B . Immunomodulatory properties of human serum immunoglobulin A: anti-inflammatory and pro-inflammatory activities in human monocytes and peripheral blood mononuclear cells. Clin Exp Immunol. 2005; 140(3):478-90. PMC: 1809399. DOI: 10.1111/j.1365-2249.2005.02779.x. View

Wolf H, Vogel E, Fischer M, Rengs H, Schwarz H, Eibl M . Inhibition of receptor-dependent and receptor-independent generation of the respiratory burst in human neutrophils and monocytes by human serum IgA. Pediatr Res. 1994; 36(2):235-43. DOI: 10.1203/00006450-199408000-00016. View

Hotchkiss R, Moldawer L, Opal S, Reinhart K, Turnbull I, Vincent J . Sepsis and septic shock. Nat Rev Dis Primers. 2017; 2:16045. PMC: 5538252. DOI: 10.1038/nrdp.2016.45. View

10.

Heineke M, van Egmond M . Immunoglobulin A: magic bullet or Trojan horse?. Eur J Clin Invest. 2016; 47(2):184-192. DOI: 10.1111/eci.12716. View

11.

Gelfand E . Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med. 2012; 367(21):2015-25. DOI: 10.1056/NEJMra1009433. View

12.

Manohar P, Loh B, Nachimuthu R, Hua X, Welburn S, Leptihn S . Secondary Bacterial Infections in Patients With Viral Pneumonia. Front Med (Lausanne). 2020; 7:420. PMC: 7419580. DOI: 10.3389/fmed.2020.00420. View

13.

Otten M, Rudolph E, Dechant M, Tuk C, Reijmers R, Beelen R . Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors. J Immunol. 2005; 174(9):5472-80. DOI: 10.4049/jimmunol.174.9.5472. View

14.

Langereis J, van der Flier M, de Jonge M . Limited Innovations After More Than 65 Years of Immunoglobulin Replacement Therapy: Potential of IgA- and IgM-Enriched Formulations to Prevent Bacterial Respiratory Tract Infections. Front Immunol. 2018; 9:1925. PMC: 6115500. DOI: 10.3389/fimmu.2018.01925. View

15.

Bakema J, van Egmond M . The human immunoglobulin A Fc receptor FcαRI: a multifaceted regulator of mucosal immunity. Mucosal Immunol. 2011; 4(6):612-24. DOI: 10.1038/mi.2011.36. View

16.

Cao W, Liu X, Hong K, Ma Z, Zhang Y, Lin L . High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China. Front Immunol. 2021; 12:627844. PMC: 7933558. DOI: 10.3389/fimmu.2021.627844. View

17.

Suzuki T, Ainai A, Hasegawa H . Functional and structural characteristics of secretory IgA antibodies elicited by mucosal vaccines against influenza virus. Vaccine. 2017; 35(39):5297-5302. DOI: 10.1016/j.vaccine.2017.07.093. View

18.

Brandsma A, Bondza S, Evers M, Koutstaal R, Nederend M, Jansen J . Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG. Front Immunol. 2019; 10:704. PMC: 6470253. DOI: 10.3389/fimmu.2019.00704. View

19.

Wilton J . Suppression by IgA of IgG-mediated phagocytosis by human polymorphonuclear leucocytes. Clin Exp Immunol. 1978; 34(3):423-8. PMC: 1537540. View

20.

Aloulou M, Ben Mkaddem S, Biarnes-Pelicot M, Boussetta T, Souchet H, Rossato E . IgG1 and IVIg induce inhibitory ITAM signaling through FcγRIII controlling inflammatory responses. Blood. 2012; 119(13):3084-96. DOI: 10.1182/blood-2011-08-376046. View